NKTR logo

NKTR

Nektar Therapeutics

$60.33
+$0.73(+1.22%)
54
Overall
--
Value
54
Tech
--
Quality
Market Cap
$1.05B
Volume
1.58M
52W Range
$6.45 - $59.58
Target Price
$96.17
Order:

Income Statement

MetricTrendChart
2015
Dec
2016
Dec
2017
Dec
2018
Dec
2019
Dec
2020
Dec
2021
Dec
2022
Dec
2023
Dec
2024
Dec
REVENUE
Total Revenue
$230.8M$165.4M$307.7M$1.2B$114.6M$152.9M$93.9M$92.1M$90.1M$98.4M
Total Revenue
$40.2M$55.4M$307.7M$1.2B$114.6M$152.9M$101.9M$92.1M$90.1M$98.4M
COST OF GOODS SOLD
Cost of Revenue
$-34.1M$-30.2M$-30.5M$-24.4M$21.4M$19.5M$24.9M$21.6M$33.8M$30.7M
GROSS PROFIT
Gross Profit
$196.7M$135.2M$261.2M$1.2B$93.2M$133.4M$77.0M$70.4M$56.4M$67.7M
OPERATING EXPENSES
Operating Expenses
$226.1M$248.1M$320.8M$481.0M$533.3M$513.4M$523.1M$310.7M$191.6M$197.7M
Research & Development
$182.8M$203.8M$268.5M$399.5M$434.6M$408.7M$400.3M$218.3M$114.2M$120.9M
Research Expense
$182.8M$203.8M$268.5M$399.5M$434.6M$408.7M$400.3M$218.3M$114.2M$120.9M
Selling, General & Administrative
$43.3M$44.3M$52.4M$81.4M$98.7M$104.7M$122.8M$92.3M$77.4M$76.8M
General & Administrative Expenses
$43.3M$44.3M$52.4M$81.4M$98.7M$104.7M$122.8M$92.3M$77.4M$76.8M
Salaries & Wages
$-19.7M$-25.9M$-36.6M$-88.1M--------$33.4M$21.6M
Depreciation & Amortization
$-11.4M$-13.2M$-12.6M$-8.8M$11.0M$12.5M$13.0M$12.2M$7.8M$4.4M
Depreciation & Amortization
$-11.4M$-13.2M$-12.6M$-8.8M$11.0M$12.5M$13.0M$12.2M$7.8M$4.4M
Amortization
--------------$78.6M$1.6M--
Other Operating Expenses
------$-8.0M$-49.9M$-2.5M$-2.4M$-378.0K$-848.0K$-582.0K
OPERATING INCOME
Operating income
$-29.4M$-112.9M$-59.6M$687.9M$-440.0M$-425.1M$-446.1M$-376.2M$-263.7M$-105.2M
EBITDA
$-69.8M$-135.4M$-79.4M$715.2M$-405.6M$-392.6M$-461.8M$-323.0M$-283.3M$-86.7M
NON-OPERATING ITEMS
Interest Expense (Non-Operating)
$18.3M$22.5M$22.1M$21.6M$21.3M$37.1M$47.3M$28.9M$25.3M$28.1M
Intinc
$-20.6M$-19.7M$-18.9M$-21.2M------$6.8M$19.0M$14.5M
Net Non-Operating Interest Income/Expense
$-38.9M$-42.2M$-41.0M$-42.8M$-21.3M$-6.9M--$22.1M$19.0M$14.5M
Gain on Sale of Securities
$42.5M$79.0K$-533.0K--------------
Other Income/Expense
$12.4M$-2.4M$-4.5M$-37.6M$-21.3M$12.0M$69.2M$-102.6M$6.2M$390.0K
Other Special Charges
$-12.4M$2.4M$4.5M$37.6M$21.3M$-12.0M$-69.2M$4.4M$-6.2M$-390.0K
SPECIAL ITEMS
Restructring And Mn A Income
--------------$135.9M$52.0M$15.7M
Special Income Charges
--------------$-135.9M$-128.5M$-15.7M
Impairment of Capital Assets
--------------$65.8M$76.5M--
PRE-TAX INCOME
EBIT
$-82.6M$-150.8M$-94.1M$704.3M$-418.7M$-406.8M$-476.0M$-336.1M$-276.3M$-91.1M
Pre-Tax Income
$-80.7M$-152.6M$-96.1M$682.7M$-440.1M$-443.9M$-523.3M$-365.0M$-276.3M$-119.2M
INCOME TAX
Tax Provision
$506.0K$876.0K$616.0K$1.4M$613.0K$493.0K$557.0K$3.2M$-200.0K$-239.0K
NET INCOME
Net Income
$-81.2M$-153.5M$-96.7M$681.3M$-440.7M$-444.4M$-523.8M$-368.2M$-276.1M$-119.0M
Net Income (Continuing Operations)
$-81.2M$-153.5M$-96.7M$681.3M$-440.7M$-444.4M$-523.8M$-368.2M$-276.1M$-119.0M
Net Income (Discontinued Operations)
$-81.2M$-153.5M$-96.7M$681.3M$-440.7M$-444.4M$-523.8M$-368.2M$-276.1M$-119.0M
Net Income (Common Stockholders)
$-81.2M$-153.5M$-96.7M$681.3M$-440.7M$-444.4M$-523.8M$-368.2M$-276.1M$-119.0M
Normalized Income
------------------$-135.8M
TOTALS
Total Expenses
$192.0M$217.9M$290.3M$456.6M$554.7M$532.8M$548.0M$332.3M$225.3M$228.3M
SHARE & EPS DATA
Average Shares Outstanding
$8.8M$9.3M$10.4M$11.3M$11.7M$11.9M$12.2M$12.5M$12.7M$205.7M
Average Shares Outstanding (Diluted)
$8.9M$9.3M$10.4M$12.0M$11.7M$11.9M$12.2M$12.5M$12.7M$205.7M
Shares Outstanding
$12.5M$12.5M$12.5M$12.5M$12.5M$12.5M$12.5M$12.6M$19.0M$186.1M
Basic EPS
$-6$-4.2$-3.15$60.3$-37.8$-37.35$-42.9$-29.55$-21.75$-0.58
Basic EPS (Continuing Operations)
--------$-37.8$-37.35$-42.9$-29.55$-21.75$-0.58
Diluted EPS
$-9.15$-16.5$-9.3$56.7$-37.8$-37.35$-42.9$-29.55$-21.75$-0.58
Diluted EPS (Continuing Operations)
--------$-37.8$-37.35$-42.9$-29.55$-21.75$-0.58
OTHER METRICS
Gain On Sale Of Business
------------------$40.4M
Gain On Sale Of P P E
------------$-8.0M$3.3M$-1.3M--
Interest Expense Operating
$-20.2M$-20.6M$-20.1M--------------
Other Gand A
$43.3M$44.3M$52.4M$81.4M$98.7M$104.7M$122.8M$92.3M$77.4M$76.8M
Other Impairment Of Capital Assets
--------------$67.9M$35.3M$8.3M
Other Write Down
$-1.6M------------------
Rent And Landing Fees
$43.3M$44.3M$52.4M$81.4M------------
Restruct
--------------$135.9M$52.0M$15.7M

Financial data is updated quarterly and may not reflect the most recent earnings.

ABCD
1SymbolPriceChangeVol
2NKTR$60.33+1.2%1.58M
3
4
5
6

Get Nektar Therapeutics Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.